Ozmosi | Cibinetide Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Cibinetide

Alternative Names: cibinetide, ara-290, ara290, ara 290
Clinical Status: Inactive
Latest Update: 2025-08-01
Latest Update Note: News Article

Product Description

Cibinetide significantly increased small nerve fiber abundance in the cornea and skin, consistent with a disease modifying effect. (Sourced from: https://iovs.arvojournals.org/article.aspx?articleid=2625918)

Mechanisms of Action: SRI Inhibitor

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Injection

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: LUMC
Company Location: Europe
Company Founding Year: 1996
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Sarcoidosis|Type 2 Diabetes|Insulin Resistance|Glucose Intolerance|Prediabetic State|Small Fiber Neuropathy|Inflammation|Neuropathic Pain|Macular Edema|Depressive Disorder|Arthritis, Rheumatoid|Complex Regional Pain Syndromes|Prediabetes

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2015-001940-12

The use of ARA 290 for the treatment of DMO (ARA 290-DMO) v1

P2

Terminated

Macular Edema

2017-08-29

2022-03-13

Treatments

NCT06626971

ARA290DMO

P2

Terminated

Macular Edema

2017-05-12

2024-10-05

Primary Endpoints|Treatments

2013-003016-45

DOSARA

P2

Completed

Small Fiber Neuropathy

2015-02-02

2022-03-13

Treatments

NCT02039687

APCP-112

P2

Completed

Sarcoidosis

2015-01-01

2019-03-20

Treatments

2012-003207-35

ARA290inT2D

P2

Completed

Type 2 Diabetes|Prediabetes

2014-12-02

2022-03-13

Treatments

NCT01933529

APCP-115

P2

Unknown status

Prediabetic State|Glucose Intolerance|Type 2 Diabetes|Insulin Resistance

2014-06-01

2019-03-19

Treatments

2012-005590-32

ARAND

P2

Active, not recruiting

Type 2 Diabetes

2013-11-20

2022-03-13

Treatments

2012-003688-24

CRPSARA

P2

Active, not recruiting

Complex Regional Pain Syndromes

2013-03-12

2022-03-13

Treatments

NCT02070783

CONEARA

P2

Completed

Depressive Disorder

2013-02-01

2019-03-20

Treatments

2010-021518-45

2010-021518-45

P2

Active, not recruiting

Neuropathic Pain

2012-07-06

2022-03-13

Treatments

2010-023469-22

ARA 290 in ARA

P2

Active, not recruiting

Arthritis, Rheumatoid

2012-03-09

2022-03-13

Treatments

2010-024364-18

Cognitive and neural effects of ARA290

P2

Active, not recruiting

Depressive Disorder

2011-10-12

2022-03-13

Treatments

2010-018584-41

2010-018584-41

P2

Active, not recruiting

Inflammation

2011-07-23

2025-07-05

Treatments